Antares Pharma — Investor Presentation (May 2006)
38 slides from Antares Pharma's investor presentation, May 5, 2006
Slide 1: Analysts & Investors Luncheon
Strictly Confidential 1 st st Analysts & Investors Luncheon Analysts & Investors Luncheon The Cornell Club, New York The Cornell Club, New York May 4, 2006 May 4, 2006 Amex: AIS Amex: AIS www.antarespharma.com www.antarespharma.com Exhibit 99.3
Slide 2: Agenda
Antares Pharma, Inc. © 2006 Confidential 2 The platform technologies and their evolution The Antares product pipeline development system Value creation through own clinical development Value creation through partnerships/alliances Anturol ATD (oxybutynin): A “show-case” example Technology proof-of-c
Slide 3: Pharmaceutical Technology Platforms
Antares Pharma, Inc. © 2006 Confidential 3 EasyTec™ Orally Disintegrating Tablets Fast-Melt Tablet Technologies TecTix™ Transdermal/Topical Technology Eutectics Semisolid Technologies Topical Delivery Technology Local ATD ™ Combination Gels ATD ™ Single Gels Systemic Advanced Transdermal Delivery (
Slide 4: Antares' Platform Technologies and their Evolution
Antares Pharma, Inc. © 2006 Confidential 4 Antares’ Platform Technologies and their Evolution Research Effort Results in 2006 There is constant on-going research on strengthening our technologies and intellectual properties. Advanced Transdermal Delivery System ATD ™ ATD ™ Permeation Enhancer • Cons
Slide 5: The Focus and Research Aim
Antares Pharma, Inc. © 2006 Confidential 5 Drug Delivery Target Antares’ Technologies with Benefits Groups a Reason for Being The Focus and Research Aim EasyTec ™ Superior “Flash” Oral Disintegrating Tablets Delivering drugs with reduced side-effects discretely and/or passively is our R&D mission. A
Slide 6: ATD Advanced Transdermal Delivery Technology
Antares Pharma, Inc. © 2006 Confidential 6 ATD™ Advanced Transdermal Delivery Technology ATD™ Transdermal Gel Technology
Slide 7: ATD Transdermal Gel Technology: What is it?
Antares Pharma, Inc. © 2006 Confidential 7 Semi-solid formulations containing one or more drugs A hydro-alcoholic vehicle A combination of permeation enhancers Thickening agents A pH regulator What is it? Increases drug partitioning into the skin Increases drug partitioning into the skin Provides su
Slide 8: ATD Platform Illustration: Mode of Action
Antares Pharma, Inc. © 2006 Confidential 8 The gel is applied onto the skin Ethanol evaporates, the drug concentration increases, forcing penetration. Co-solvents help avoid drug crystallization Penetration enhancers increase skin permeability resulting in drug delivery through the skin The drug is
Slide 9: ATD Platform Summary: Unique Features
Antares Pharma, Inc. © 2006 Confidential 9 Validate technology with products being reviewed by FDA Most proven versatile transdermal technology (several therapeutic area) Proven delivery efficiency (Bio-E-Gel vs. Estrasorb) Several ATD products with extensive clinical experience High skin tolerabili
Slide 10: ATD Transdermal Gel Intellectual Property Status
Antares Pharma, Inc. © 2006 Confidential 10 ATD I Core formulation patent Estrogens, Progestins or mixture thereof HRT, contraception PCT 2001 extension to 4 additional therapeutic classes ATD II: Antares/BioSante co - applications Androgens and/or Estrogens or Progestins Hormonal disorders in men a
Slide 11: TecTix Technology for Dermatology Application
Antares Pharma, Inc. © 2006 Confidential 11 Eutectics Semisolid Technologies TecTix™ Transdermal/Topical Technology TecTix™ Technology for Dermatology Application
Slide 12: TecTix: What is it?
Antares Pharma, Inc. © 2006 Confidential 12 Melting point depression of active pharmaceutical ingredients (API) by Chemical Fragrance & Flavors Ingredients (CFFI) Versatile technology that is compatible with numerous API’s Alcohol-free Patent-pending Technology What is it? TecTix™ Technology for Der
Slide 13: TecTix Advantages
Antares Pharma, Inc. © 2006 Confidential 13 CFFI with a long and safe history of use in perfumes and cosmetics High thermodynamic activity; high concentration of the API in the eutectic mixture (up to 90% w/w) Increase of lipophilic properties increased solubility in lipid membranes Higher dissoluti
Slide 14: Fast Melt Tablets: EasyTec
Antares Pharma, Inc. © 2006 Confidential 14 Fast Melt Tablets Easy Tec™ Orally Disintegrating Tablet Technology
Slide 15: EasyTec ODT: What is it?
Antares Pharma, Inc. © 2006 Confidential 15 - Hygroscopic disintegrant(s) - Water-soluble components - Large surface area (high porosity) - Large amount of disintegrants BUT leads to soft, friable, moisture-sensitive tablets BUT leads to low drug loading / large tablets The ideal ODT technology shal
Slide 16: EasyTec Orally Disintegrating Tablet Technology
Antares Pharma, Inc. © 2006 Confidential 16 Easy Tec™ Orally Disintegrating Tablet Technology
Slide 17: EasyTec Advantages
Antares Pharma, Inc. © 2006 Confidential 17 Simple, cost-effective direct compression technology Patented technology, new application filed recently Use of a type-C polymethacrylate coating polymer as the primary disintegrating agent Superior palatability Robust tablets allowing conventional packagi
Slide 18: Anturol: Assets in Late Stage Clinical Development
Antares Pharma, Inc. © 2006 Confidential 18 Fast onset of thera- peutic activity Decreased incidence of side-effects compared to oral and patch Lower topical/site irritation Accurate, improved once-daily dosing More dose flexibility than patch Clinical Phase Summary Dose proportionality found in the
Slide 19: Anturol Phase II Results: Dose Proportionality
Antares Pharma, Inc. © 2006 Confidential 19 We are pleased with our plasma profiles. ATD ™ Oxybutynin Gel: Anturol ™ – Phase II Results 0 2 4 6 8 10 0 24 48 72 96 120 144 168 192 216 240 264 288 312 336 360 384 408 432 456 480 504 528 552 576 600 Time (Hours) High Intermediate Low Dose Proportionali
Slide 20: Anturol Phase II Results: DEO and OXY Cavg
Antares Pharma, Inc. © 2006 Confidential 20 ATD ™ Oxybutynin Gel: Anturol ™ – Phase II Results DEO and OXY C avg (Surrogates of Efficacy) 10.1 4.5 4.2 3.0 4.3 5.4 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 DITROPAN IR tablet 15mg/d DITROPAN XL tablet 15mg/d OXYTROL patch 36mg ANTUROL gel low dose A
Slide 21: Anturol Market Positioning
Antares Pharma, Inc. © 2006 Confidential 21 ATD ™ Oxybutynin Gel: Anturol ™ – Market Positioning Our innovative Overactive Bladder product will have… Fast onset of therapeutic activity Decreased incidence of systemic SE Lower incidence of local irritation Once-daily dosing More flexibility and discr
Slide 22: Anturol Overview
Antares Pharma, Inc. © 2006 Confidential 22 Easy to apply and excellent skin tolerability: anticipated better patient compliance Phase III trial design and dosing confirmed at the FDA meeting Worldwide rights controlled by Antares Pharma US market expected to exceed $3.0 Billion in 2008 Overview R&D
Slide 23: Anturol Development Status
Antares Pharma, Inc. © 2006 Confidential 23 Formulation development Completed First PK study in human Completed IND filing Completed Phase II study and report Completion in Jan 06 Tech-transfer Completion in Apr 06 End of Phase II meeting Completion in May 06 Anturol ATD™ Gel R&D Assets in Late Stag
Slide 24: Pharma ATD Partnered Products
Antares Pharma, Inc. © 2006 Confidential 24 Pharma ATD™ Partnered Products Pre-clinical Company not disclosed Dermal field Undisclosed AP-1120 Pre-clinical work is being finalized Phase I planned in 3Q Company not disclosed CNS disorder Undisclosed AP-1117 Phase I/II completed BioSante (NA) Solvay (
Slide 25: Pipeline Development: Women's Health Product
Antares Pharma, Inc. © 2006 Confidential 25 Rationale – Antares’ ATD™ formulation for a combination contraceptive product with existing active compound will allow improved patient compliance . The transdermal contraceptive market has been a rapidly growing segment of the U.S. contraceptive market. O
Slide 26: Co-Development: Women's Health Product
Antares Pharma, Inc. © 2006 Confidential 26 Rationale – Antares’ ATD™ formulation for a combination contraceptive product with new active compound will allow improved patient compliance. The U.S. market was worth $2.5 billion in 2005. While oral contraceptives are expected to continue to dominate, p
Slide 27: Market Situation: Women's Health Products
Antares Pharma, Inc. © 2006 Confidential 27 J&J 22% Sonstige 14% Barr 11% Wyeth 9% Akzo Nobel 9% Schering AG 26% Watson 9% 2005 Global Market Share of Hormonal Contraceptives IMS and Kalorama Estimate Global market for contraceptives was estimated at $5.5 billion in 2005, with Schering AG as the mar
Slide 28: Product Partnering: Bio-E-Gel
Antares Pharma, Inc. © 2006 Confidential 28 Rationale – Antares’ ATD™ formulation demonstrates lowest effective dose and therapy of choice in treating postmenopausal symptoms. The U.S. and European estradiol market, in treating hot flashes and vaginal atrophy, is worth $1.4 billion. Approximately 54
Slide 29: Product Partnering: Libi-Gel
Antares Pharma, Inc. © 2006 Confidential 29 Rationale – Antares’ ATD™ formulation demonstrates almost 240% increase in frequency of sexual activity. Presently no approved product in U.S. however P&G’s Intrinsa™ patch can provide basis for approval. 2006 Phase III Targeted by Partner Phase II complet
Slide 30: Product Partnering: CNS Product
Antares Pharma, Inc. © 2006 Confidential 30 Rationale – Antares’ ATD™ system will benefit the specific CNS population allowing preferred dosing & elimination of first pass metabolism. Since being launched in the U.S., the volume of new prescriptions for oral innovator product has quadrupled resultin
Slide 31: Market Situation: CNS Product
Antares Pharma, Inc. © 2006 Confidential 31 Targeted Disease Market is Forecasted to Grow to $3.3 Billion. Market Situation - CNS Product
Slide 32: Pipeline Development: CNS Product (AP-1002)
Antares Pharma, Inc. © 2006 Confidential 32 Rationale for AP-1002 – Antares’ ATD™ system will benefit anxiety / phobia population allowing once daily dosing & elimination of first pass metabolism. Consistent and potentially lower dose release of alprazolam throughout the day, offering patients who s
Slide 33: Market Situation: CNS Product
Antares Pharma, Inc. © 2006 Confidential 33 U.S. Benzodiazepine Market was approximately $600 million in 2004 Diazepam 14% Lorazepam 20% Clonazepam 16% Temazepam 10% Alprazolam 40% Market Situation - CNS Product
Slide 34: Preclinical Pipeline
Antares Pharma, Inc. © 2006 Confidential 34 Pharma ATD™ Pharma ATD™ Preclinical Pipeline Preclinical Pipeline Expired Market: $1.6 Bil Oncology AP-1077 Expired Total soft-tissue injury market: $2.5 Bil Rheumatology AP-1100 Expired Market: $2.3 Bil 16% market share Oncology AP-1121 Expired ~5% of pre
Slide 35: Pharma EasyTec Tablet Product: AP-159 ODT Accomplishments
Antares Pharma, Inc. © 2006 Confidential 35 Formulation development Completed In vitro dissolution test on final prototype Completed April 06 Manufacturing Tech-transfer Completed April 06 AP-159 ODT Accomplishments Pharma Easy Tec™ Tablet Product
Slide 36: Summary of Development Achievements
Antares Pharma, Inc. © 2006 Confidential 36 Continued to develop new intellectual property for both oral and transdermal platforms. Focused on reduced side-effects while providing discrete and passive delivery. Researched and selected a pipeline of molecules with “blockbuster” potential for clinical
Slide 37: Pharma Business Objectives 2006
Antares Pharma, Inc. © 2006 Confidential 37 Summary of Objectives Initiation of Phase III clinical study for Anturol ATD™ gel File ANDA for AP-159 Easy Tec™ tablet Identify ex-U.S. partner for Bio-E-Gel Initiation of Phase I for AP-1117 Initiation of Phase I program(s) currently in pre-clinical phas
Slide 38: Strictly
Strictly Confidential